Inhibition of the NF-κB activation pathway has gained increasing interest in the treatment of several diseases including asthma, chronic obstructive pulmonary disease, and inflammation-associated cancer [60], [61] because of its anti-inflammatory effects. Here, NFKB1 is linked to asthma.